4.3 Review

Parsing interindividual drug variability: an emerging role for systems pharmacology

Publisher

WILEY
DOI: 10.1002/wsbm.1302

Keywords

-

Funding

  1. NW England MRC Training Scheme in Clinical Pharmacology
  2. MRC Centre for Drug Safety Science
  3. MRC [MR/L006758/1, G1000417] Funding Source: UKRI
  4. Medical Research Council [G1000417, MR/L006758/1] Funding Source: researchfish
  5. National Institute for Health Research [ACF-2012-07-001, NF-SI-0512-10064] Funding Source: researchfish

Ask authors/readers for more resources

There is notable interindividual heterogeneity in drug response, affecting both drug efficacy and toxicity, resulting in patient harm and the inefficient utilization of limited healthcare resources. Pharmacogenomics is at the forefront of research to understand interindividual drug response variability, but although many genotype-drug response associations have been identified, translation of pharmacogenomic associations into clinical practice has been hampered by inconsistent findings and inadequate predictive values. These limitations are in part due to the complex interplay between drug-specific, human body and environmental factors influencing drug response and therefore pharmacogenomics, whilst intrinsically necessary, is by itself unlikely to adequately parse drug variability. The emergent, interdisciplinary and rapidly developing field of systems pharmacology, which incorporates but goes beyond pharmacogenomics, holds significant potential to further parse interindividual drug variability. Systems pharmacology broadly encompasses two distinct research efforts, pharmacologically-orientated systems biology and pharmacometrics. Pharmacologically-orientated systems biology utilizes high throughput omics technologies, including next-generation sequencing, transcriptomics and proteomics, to identify factors associated with differential drug response within the different levels of biological organization in the hierarchical human body. Increasingly complex pharmacometric models are being developed that quantitatively integrate factors associated with drug response. Although distinct, these research areas complement one another and continual development can be facilitated by iterating between dynamic experimental and computational findings. Ultimately, quantitative data-derived models of sufficient detail will be required to help realize the goal of precision medicine. WIREs Syst Biol Med 2015, 7:221-241. doi: 10.1002/wsbm.1302 For further resources related to this article, please visit the . Conflict of interest: The authors have declared no conflicts of interest for this article.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Pharmacology & Pharmacy

Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials

Innocent G. Asiimwe, Sudeep P. Pushpakom, Richard M. Turner, Ruwanthi Kolamunnage-Dona, Andrea L. Jorgensen, Munir Pirmohamed

Summary: The latest randomized controlled trials provide moderate to high-certainty evidence that cardiovascular drugs, such as ACEIs/ARBs, are not associated with poor COVID-19 outcomes. Therefore, these drugs should not be discontinued unless they are not needed for currently approved therapeutic indications.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

Editorial Material Pharmacology & Pharmacy

Pharmacogenomics: Relevance and opportunities for clinical pharmacology

Richard M. Turner, Emma F. Magavern, Munir Pirmohamed

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

Article Pharmacology & Pharmacy

Similarity and consistency assessment of three major online drug-drug interaction resources

Elpida Kontsioti, Simon Maskell, Amina Bensalem, Bhaskar Dutta, Munir Pirmohamed

Summary: This study aimed to explore the agreement levels of drug-drug interaction information in three major online drug information resources. There was considerable variation in DDIs included in the examined DIRs, along with variability in severity categorisation and clinical advice given. DDIs labelled as critical were more likely to appear in multiple DIRs. Such variability in information could have deleterious consequences for patient safety, highlighting the need for harmonisation and standardisation.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

Article Allergy

Pharmacogenomics of Drug Hypersensitivity Technology and Translation

Rebecca Kuruvilla, Kathryn Scott, Sir Munir Pirmohamed

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2022)

Article Multidisciplinary Sciences

A reference set of clinically relevant adverse drug-drug interactions

Elpida Kontsioti, Simon Maskell, Bhaskar Dutta, Munir Pirmohamed

Summary: The accurate and timely detection of adverse drug-drug interactions (DDIs) during the postmarketing phase is important. This study proposes a scalable approach for generating a reference set for DDIs by automatically extracting and aggregating information from multiple clinical resources, supporting research in postmarketing safety surveillance.

SCIENTIFIC DATA (2022)

Article Pharmacology & Pharmacy

Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype

Roseann S. Gammal, Munir Pirmohamed, Andrew A. Somogyi, Sarah A. Morris, Christine M. Formea, Amanda L. Elchynski, Kazeem A. Oshikoya, Howard L. McLeod, Cyrine E. Haidar, Michelle Whirl-Carrillo, Teri E. Klein, Kelly E. Caudle, Mary Relling

Summary: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with the development of acute hemolytic anemia in the presence of oxidative stress. This guideline provides information on using G6PD genotype for diagnosing G6PD deficiency and categorizes medications based on their risk level in individuals with G6PD deficiency. High-risk medications should be avoided, medium-risk medications should be used with caution, and low-risk medications can be used without considering the G6PD phenotype.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Article Pharmacology & Pharmacy

Analysis of serum microRNA-122 in a randomized controlled trial of N-acetylcysteine for treatment of antituberculosis drug-induced liver injury

Muhammed Shiraz Moosa, Giusy Russomanno, Jeffrey R. Dorfman, Hannah Gunter, Chandni Patel, Eithne Costello, Dan Carr, Gary Maartens, Munir Pirmohamed, Christopher Goldring, Karen Cohen

Summary: This study investigated the concentrations of miR-122 in participants with antituberculosis drug-induced liver injury (AT-DILI) and its correlation with alanine aminotransferase (ALT) concentrations. The study found that miR-122 concentrations in AT-DILI patients were significantly higher than those in healthy volunteers and in patients on antituberculosis therapy without liver injury, and N-acetylcysteine (NAC) had no effect on miR-122 concentrations.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Article Pharmacology & Pharmacy

Clinical Relevance of Drug-Drug Interactions With Antibiotics as Listed in a National Medication Formulary: Results From Two Large Population-Based Case-Control Studies in Patients Aged 65-100 Years Using Linked English Primary Care and Hospital Data

Tjeerd Pieter van Staa, Munir Pirmohamed, Anita Sharma, Iain Buchan, Darren M. Ashcroft

Summary: This study evaluated drug-drug interactions (DDIs) between antibiotics and nonantibiotic drugs listed with warnings of severe outcomes in the British National Formulary. The results showed no substantial risk of DDIs despite the warnings in the national formulary.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Review Genetics & Heredity

Pharmacogenomics: current status and future perspectives

Munir Pirmohamed

Summary: In this Review, the current state of the pharmacogenomics field is discussed, along with clinically relevant drug-gene associations and the steps required for implementing pharmacogenomics into clinical practice. The role of pharmacogenomics in drug discovery and development is also considered. The variability in drug response between individuals, which can be attributed to genomic factors, is a global concern. Despite the availability and decreasing cost of genotyping technologies, challenges in implementing pharmacogenomics lie in adapting current clinical pathways and addressing the knowledge gap in healthcare professionals. Furthermore, pharmacogenomics shows promise in enhancing drug discovery and development outcomes.

NATURE REVIEWS GENETICS (2023)

Article Public, Environmental & Occupational Health

Exploring the impact of design criteria for reference sets on performance evaluation of signal detection algorithms: The case of drug-drug interactions

Elpida Kontsioti, Simon Maskell, Munir Pirmohamed

Summary: This study aimed to evaluate the impact of multiple design criteria for reference sets used to assess the performance of signal detection algorithms for drug-drug interactions. Custom-made reference sets of different sizes were generated based on various design criteria. The performance metrics of three algorithms were assessed using FDA Adverse Event Reporting System data, and the results showed that the composition of reference sets significantly impacted the evaluation metrics.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2023)

Review Geriatrics & Gerontology

Interventions for reducing anticholinergic medication burden in older adults-a systematic review and meta-analysis

Eve Braithwaite, Oliver M. Todd, Abigail Atkin, Rachel Hulatt, Ragy Tadrous, David P. Alldred, Munir Pirmohamed, Lauren Walker, Rebecca Lawton, Andrew Clegg

Summary: A systematic review with meta-analysis was conducted to examine interventions aimed at reducing anticholinergic burden in older adults. The results showed no significant difference in outcomes between control and intervention group for falls, cognition, anticholinergic burden, or quality of life. Short follow-up time and lack of training and support surrounding successful deprescribing may have contributed to these results.

AGE AND AGEING (2023)

Article Pharmacology & Pharmacy

A Survey of the UK Pharmacy Profession's Educational Needs on Pharmacogenomics

Victoria Rollinson, Neil French, Richard Turner, Munir Pirmohamed

Summary: This study aimed to assess the current educational status of pharmacogenomics within the UK pharmacy profession and identify future educational and infrastructure needs of pharmacists. A survey was conducted among practicing pharmacists, preregistration pharmacists, and MPharm students. The findings indicate the need for further education and the development of PGx guidelines to prepare the pharmacy workforce for PGx implementation.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2023)

Article Public, Environmental & Occupational Health

Adverse drug reactions and hospital admissions: Large case-control study of patients aged 65-100 years using linked English primary care and hospital data

Tjeerd Pieter van Staa, Munir Pirmohamed, Anita Sharma, Darren M. M. Ashcroft, Iain Buchan

Summary: This study aims to assess the relationship between medication classes and adverse drug reactions (ADR) and emergency hospital admission. Through big data analysis, it was found that certain medication classes have a higher risk of ADR-related hospitalization. Therefore, there is a need for regular systematic assessment of the harm-benefit ratio of medicines.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2023)

Article Multidisciplinary Sciences

ADRA2A and IRX1 are putative risk genes for Raynaud's phenomenon

Sylvia Hartmann, Summaira Yasmeen, Benjamin M. Jacobs, Spiros Denaxas, Munir Pirmohamed, Eric R. Gamazon, Mark J. Caulfield, Harry Hemingway, Maik Pietzner, Claudia Langenberg

Summary: The study identified three novel genomic regions related to Raynaud's phenomenon risk, prioritized candidate causal genes, and revealed a likely detrimental effect of low fasting glucose levels on RP risk. The research also highlighted opportunities for drug repurposing and provided robust evidence for a strong genetic contribution to RP.

NATURE COMMUNICATIONS (2023)

Article Gastroenterology & Hepatology

Role of fatty liver index in risk-stratifying comorbid disease outcomes in non-alcoholic fatty liver disease

Brian Ho, Andrew Thompson, Andrea L. Jorgensen, Munir Pirmohamed

Summary: This study assessed the utility of the fatty liver index (FLI) for risk stratification of non-alcoholic fatty liver disease (NAFLD) and associated comorbidities. The results showed that FLI can effectively identify the risk of NAFLD and related comorbidities, including cardiovascular metabolic diseases and malignant tumors, and is closely associated with all-cause mortality risk.

JHEP REPORTS (2023)

No Data Available